AdAlta Salute del bilancio

Salute finanziaria criteri di controllo 3/6

AdAlta ha un patrimonio netto totale di A$2.0M e un debito totale di A$2.6M, che porta il suo rapporto debito/patrimonio netto a 128.3%. Le sue attività totali e le sue passività totali sono rispettivamente A$5.6M e A$3.5M.

Informazioni chiave

128.3%

Rapporto debito/patrimonio netto

AU$2.61m

Debito

Indice di copertura degli interessi	n/a
Contanti	AU$3.13m
Patrimonio netto	AU$2.03m
Totale passività	AU$3.54m
Totale attività	AU$5.57m

Aggiornamenti recenti sulla salute finanziaria

Recent updates

Is AdAlta (ASX:1AD) A Risky Investment?

Oct 11

Shareholders May Find It Hard To Justify Increasing AdAlta Limited's (ASX:1AD) CEO Compensation For Now

Nov 16

Is AdAlta (ASX:1AD) Using Debt Sensibly?

Sep 02

We're Not Very Worried About AdAlta's (ASX:1AD) Cash Burn Rate

Jun 11

Companies Like AdAlta (ASX:1AD) Are In A Position To Invest In Growth

Feb 26

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( A$5.3M ) di 1AD superano le sue passività a breve termine ( A$2.2M ).

Passività a lungo termine: Le attività a breve termine di 1AD ( A$5.3M ) superano le sue passività a lungo termine ( A$1.3M ).

Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: 1AD ha più liquidità del suo debito totale.

Riduzione del debito: Il rapporto debito/patrimonio netto di 1AD è aumentato da 0% a 128.3% negli ultimi 5 anni.

Bilancio

Analisi della pista di contanti

Per le società che in passato sono state mediamente in perdita, valutiamo se hanno almeno un anno di liquidità.

Pista di liquidità stabile: 1AD ha meno di un anno di cash runway in base al suo attuale free cash flow.

Previsione Cash Runway: 1AD ha meno di un anno di liquidità disponibile se il flusso di cassa libero continua a ridursi ai tassi storici del 0 % ogni anno

AdAlta Salute del bilancio

Salute finanziaria criteri di controllo 3/6

Informazioni chiave

Aggiornamenti recenti sulla salute finanziaria

Is AdAlta (ASX:1AD) A Risky Investment?

Is AdAlta (ASX:1AD) Using Debt Sensibly?

We're Not Very Worried About AdAlta's (ASX:1AD) Cash Burn Rate

Companies Like AdAlta (ASX:1AD) Are In A Position To Invest In Growth

Recent updates

AdAlta Limited Appoints Kevin Lynch as Consultant Chief Medical Officer of AdCella

AdAlta Limited, Annual General Meeting, Nov 20, 2024

Is AdAlta (ASX:1AD) A Risky Investment?

New major risk - Shareholder dilution

New major risk - Financial position

AdAlta Limited has completed a Follow-on Equity Offering in the amount of AUD 1.66 million.

AdAlta Limited has completed a Follow-on Equity Offering in the amount of AUD 1.66 million.

New major risk - Financial position

AdAlta Limited has filed a Follow-on Equity Offering in the amount of AUD 1.23 million.

AdAlta Limited, Annual General Meeting, Nov 22, 2023

New major risk - Financial position

AdAlta Limited has completed a Follow-on Equity Offering in the amount of AUD 3.153759 million.

First half 2023 earnings released: AU$0.009 loss per share (vs AU$0.015 loss in 1H 2022)

Shareholders May Find It Hard To Justify Increasing AdAlta Limited's (ASX:1AD) CEO Compensation For Now

Less than half of directors are independent

AdAlta Limited Provides an Update on Its Lead Program, AD-214

AdAlta Limited, Annual General Meeting, Nov 22, 2022

AdAlta Limited, Annual General Meeting, Nov 22, 2022

Is AdAlta (ASX:1AD) Using Debt Sensibly?

Full year 2022 earnings released: AU$0.022 loss per share (vs AU$0.024 loss in FY 2021)

AdAlta Limited Modifies the Sequencing of AD-214 Manufacturing Campaigns and Toxicology Studies

Price target increased to AU$0.27

Less than half of directors are independent

Adalta Limited Finalizes Reclinical Development Program to Develop Inhaled Version of AD-214

First half 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

AdAlta Limited has completed a Follow-on Equity Offering in the amount of AUD 1.253406 million.

Full year 2021 earnings released: AU$0.024 loss per share (vs AU$0.037 loss in FY 2020)

We're Not Very Worried About AdAlta's (ASX:1AD) Cash Burn Rate

First half 2021 earnings released: AU$0.021 loss per share (vs AU$0.037 loss in 1H 2020)

Companies Like AdAlta (ASX:1AD) Are In A Position To Invest In Growth

AdAlta Receives Orphan Drug Designation from the US Food and Drug Administration for Its Lead Product Candidate AD-214 for the Treatment of Idiopathic Pulmonary Fibrosis

AdAlta Limited Announces Phase I HV Extension to Explore Encouraging Results

AdAlta Limited Announces the Extension of its Collaboration with GE Healthcare

AdAlta Limited has completed a Follow-on Equity Offering in the amount of AUD 4 million.

AdAlta Limited has completed a Follow-on Equity Offering in the amount of AUD 4.09864 million.

Full year earnings released - AU$0.037 loss per share

Analisi della posizione finanziaria

Storia e analisi del rapporto debito/patrimonio netto

Bilancio

Analisi della pista di contanti

Scoprire le aziende sane